Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 17 studies | 44% ± 18% | |
peripheral blood | 17 studies | 35% ± 10% | |
intestine | 13 studies | 28% ± 15% | |
brain | 9 studies | 33% ± 13% | |
kidney | 9 studies | 40% ± 18% | |
eye | 7 studies | 35% ± 14% | |
liver | 6 studies | 39% ± 14% | |
placenta | 5 studies | 37% ± 13% | |
uterus | 5 studies | 43% ± 16% | |
pancreas | 4 studies | 35% ± 3% | |
breast | 4 studies | 27% ± 9% | |
bone marrow | 3 studies | 30% ± 13% | |
adrenal gland | 3 studies | 35% ± 10% | |
esophagus | 3 studies | 41% ± 19% | |
lymph node | 3 studies | 41% ± 35% | |
skin | 3 studies | 29% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 40612.70 | 226 / 226 | 100% | 408.46 | 406 / 406 |
thymus | 100% | 23949.91 | 651 / 653 | 100% | 247.87 | 603 / 605 |
kidney | 100% | 88790.33 | 89 / 89 | 99% | 540.81 | 894 / 901 |
prostate | 100% | 22609.07 | 245 / 245 | 99% | 168.50 | 498 / 502 |
adrenal gland | 100% | 101991.29 | 258 / 258 | 99% | 285.01 | 227 / 230 |
skin | 100% | 33004.91 | 1808 / 1809 | 99% | 409.80 | 466 / 472 |
esophagus | 99% | 20922.42 | 1433 / 1445 | 99% | 148.11 | 182 / 183 |
pancreas | 100% | 19056.01 | 327 / 328 | 99% | 357.53 | 176 / 178 |
uterus | 100% | 17941.96 | 170 / 170 | 98% | 259.54 | 450 / 459 |
lung | 100% | 68629.24 | 578 / 578 | 98% | 309.42 | 1129 / 1155 |
intestine | 100% | 28921.37 | 965 / 966 | 98% | 190.91 | 515 / 527 |
breast | 100% | 29801.60 | 459 / 459 | 97% | 334.33 | 1088 / 1118 |
bladder | 100% | 31666.95 | 21 / 21 | 97% | 304.51 | 487 / 504 |
stomach | 100% | 26359.11 | 359 / 359 | 96% | 172.59 | 275 / 286 |
ovary | 99% | 13642.70 | 178 / 180 | 94% | 139.14 | 404 / 430 |
brain | 95% | 15070.45 | 2513 / 2642 | 92% | 122.95 | 650 / 705 |
adipose | 100% | 36990.11 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 509.33 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 616.15 | 29 / 29 |
spleen | 100% | 63609.59 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 262.09 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 170.50 | 1 / 1 |
blood vessel | 100% | 43242.35 | 1330 / 1335 | 0% | 0 | 0 / 0 |
muscle | 99% | 35162.82 | 796 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 34525.99 | 836 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 86% | 47062.18 | 800 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000045 | Biological process | autophagosome assembly |
GO_0038020 | Biological process | insulin receptor recycling |
GO_0070201 | Biological process | regulation of establishment of protein localization |
GO_0043280 | Biological process | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0042159 | Biological process | lipoprotein catabolic process |
GO_0006508 | Biological process | proteolysis |
GO_1901143 | Biological process | insulin catabolic process |
GO_0019886 | Biological process | antigen processing and presentation of exogenous peptide antigen via MHC class II |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0045121 | Cellular component | membrane raft |
GO_0035580 | Cellular component | specific granule lumen |
GO_0005764 | Cellular component | lysosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_1904724 | Cellular component | tertiary granule lumen |
GO_1904813 | Cellular component | ficolin-1-rich granule lumen |
GO_0010008 | Cellular component | endosome membrane |
GO_0043202 | Cellular component | lysosomal lumen |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0042470 | Cellular component | melanosome |
GO_0031904 | Cellular component | endosome lumen |
GO_0070001 | Molecular function | aspartic-type peptidase activity |
GO_0008233 | Molecular function | peptidase activity |
GO_0004190 | Molecular function | aspartic-type endopeptidase activity |
GO_0004197 | Molecular function | cysteine-type endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CTSD |
Protein name | Cathepsin D isoform 2 Cathepsin D (EC 3.4.23.5) Cathepsin D (EC 3.4.23.5) [Cleaved into: Cathepsin D light chain; Cathepsin D heavy chain] Cathepsin D |
Synonyms | HEL-S-130P CPSD hCG_49857 |
Description | FUNCTION: Acid protease active in intracellular protein breakdown. Plays a role in APP processing following cleavage and activation by ADAM30 which leads to APP degradation . Involved in the pathogenesis of several diseases such as breast cancer and possibly Alzheimer disease. . |
Accessions | F8W787 P07339 ENST00000637815.2 A0A1B0GW44 ENST00000433655.6 ENST00000429746.2 ENST00000236671.7 ENST00000637387.1 ENST00000678991.1 A0A0S2Z3L4 C9JH19 A0A1B0GVP3 ENST00000367196.4 A0A1B0GV23 ENST00000636571.1 ENST00000637915.1 A0A1B0GWE8 ENST00000636843.1 ENST00000438213.6 V9HWI3 F8WD96 A0A7I2V2N3 A0A1B0GVD5 |